Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,520.00 | |
50 mg | 6-8 weeks | $ 1,980.00 | |
100 mg | 6-8 weeks | $ 2,500.00 |
Description | Nuvenzepine is an antagonist of mAChR. It has the potential for gastrospasm treatment. |
In vitro | Nuvenzepine demonstrates nearly equal potency to pirenzepine in competitively inhibiting bethanechol-induced gallbladder contractions and exhibits a four-fold greater potency in preventing vagal-stimulated tracheal constrictions. Additionally, it has a four-fold higher affinity than pirenzepine in competitively antagonizing acetylcholine-induced contractions in both isolated ileal musculature and longitudinal ileum dispersed cells [1]. |
In vivo | Nuvenzepine, distinct from pirenzepine, actively moderates colonic motility and, when administered intraduodenally in anaesthetized cats, exhibits a prolonged, dose-dependent suppression of neostigmine-induced intestinal movement. This compound significantly reduces gastric acid secretion and intestinal hypermotility in rats while manifesting minimal atropine-like side effects. It is characterized by slow oral absorption, with an absolute bioavailability of 30 to 40%, slow elimination, negligible accumulation in the body, and minimal metabolism. Notably, Nuvenzepine's efficacy in inhibiting ileal motor activity is tenfold that of pirenzepine and demonstrates a 25-30 times higher potency in suppressing pentagastrin-stimulated gastric acid secretion in conscious cats, indicating its significant therapeutic potential. |
Molecular Weight | 336.39 |
Formula | C19H20N4O2 |
CAS No. | 96487-37-5 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Nuvenzepine 96487-37-5 Angiogenesis JAK/STAT signaling Tyrosine Kinase/Adaptors EGFR inhibitor inhibit